■随着GLP-1受体激动剂的兴起,患者注意到寻常痤疮的副作用,这些副作用似乎与药物的同时治疗有关。由于这些药物在美国市场相对较新的出现和它们的高需求之间的对应关系,重要的是调查目前文献中已知的内容,以便患者能够得到适当的信息。
■本研究的目的是调查两者之间的关系,或缺乏,胰高血糖素样肽1(GLP-1)受体激动剂的使用与患者痤疮相关的副作用之间的关系。
■对6种GLP-1受体激动剂(3种每周一次给药方案,和3,每日一次给药时间表)在PubMed在线数据库上进行。布尔标准用于缩小搜索范围。荟萃分析中包括45篇符合搜索标准的研究文章。
■搜索结果显示,从以下长效GLP-1受体激动剂中,杜拉鲁肽,艾塞那肽延长释放,和塞马鲁肽(Wegovy),没有确凿的痤疮副作用的报道。此外,结果还表明,从以下短效GLP-1受体激动剂,利拉鲁肽,利西拉来,和塞马鲁肽(Rybelsus),没有确凿的痤疮副作用的报道。
■本研究的局限性包括关于GLP-1激动剂与寻常痤疮之间关系的有限文献。
GLP-1激动剂本身不太可能直接导致一些患者在治疗期间可能发展的痤疮。相反,更有可能的是,这些药物治疗导致的体重减轻可能会引起内在的生理和激素变化,从而诱发或加剧此类患者的寻常痤疮.
UNASSIGNED: With the emerging popularity of GLP-1 receptor agonists, patients are noticing acne vulgaris side effects that are seemingly related to the concurrent treatment with the drug. Due to the correspondence between these drugs\' relatively recent emergence in the U.S. market and their high demand, it is important to investigate what is currently known in the literature so that patients can be properly informed.
UNASSIGNED: The aim of this study is to investigate the relationship, or lack thereof, between glucagon like peptide 1 (GLP-1) receptor agonist usage and acne-related side effects in patients.
UNASSIGNED: A web-based analysis of 6 GLP-1 receptor agonists (3 with a once-weekly dosing schedule, and 3 with a once-daily dosing schedule) was conducted on PubMed online database. Boolean criteria were used to narrow the search. Included in the meta-analysis were 45 research articles that fulfilled the search criteria.
UNASSIGNED: The results of the search showed that from the following long-acting GLP-1 receptor agonists, dulaglutide, exenatide extended release, and semaglutide (Wegovy), no conclusive acne side effects were reported. In addition, the results also showed that from the following short-acting GLP-1 receptor agonists, liraglutide, lixisenatide, and semaglutide (Rybelsus), no conclusive acne side effects were reported.
UNASSIGNED: Limitations of this study include a limited amount of literature regarding the relationship between GLP-1 agonists and acne vulgaris.
UNASSIGNED: It is unlikely that GLP-1 agonists themselves are directly responsible for the acne that some patients may develop during treatment. Rather, it is more probable that the weight loss yielded by treatment with these drugs may induce intrinsic physiologic and hormonal changes that induce or exacerbate acne vulgaris in such patients.